In comparing CRC and benign lesions, the OR of methylated SFRP2 for the MSP subgroup was 3.38 (95% CI: 1.27–8.96), and the OR for the non-MSP subgroup was 7.24 (95% CI: 4.40–11.91). This evidence concerns the gene SFRP2 and colorectal carcinoma.